Since the discovery in 1997 of a major tumor suppressor gene encoding a protein with tyrosine phosphatase activity-which was named PTEN (phosphatase and tensin homolog on chromosome ten), MMAC1, or TEP1 (1-3)-an outburst of publications have documented the relevance of PTEN (currently used protein name; offi cial gene name PTEN) on tumor biology and human disease (4) . The human PTEN gene is located at chromosome 10q23, a locus frequently deleted in human cancers. In addition, PTEN is a common target of point mutations in tumors, including mutations at noncoding and nontranslated regions, as well as frameshift, missense, and nonsense mutations at coding regions. Patients with PHTS (PTEN hamartoma tumor syndrome), as well as a fraction of patients with ASD (autism spectrum disorders), carry germline PTEN mutations. In the case of PHTS patients, this confers high risk for several types of cancer, including (but not restricted to) breast and thyroid cancer (5) (6) (7) . PTEN mutations at coding regions distribute all along the gene, and mutations are common in exons encoding the protein tyrosine phosphatase (PTP) catalytic domain, especially exon 5 (8) . Although a large number of PTEN mutations found in tumors or in PHTS patients confer total loss of function to the protein, many mutations lead to partial loss of function or have a weak effect on PTEN phosphatase activity. Moreover, most of the germline PTEN mutations from ASD patients do not abrogate PTEN catalysis (9) . This makes important not only identifying the PTEN mutation affecting the patient but also characterization of the functional properties of the corresponding mutated PTEN protein.
PTEN is one of relatively few genes in the human genome that encodes two proteins by noncanonical alternative initiation of translation (Fig. 1A) . The shorter and more abundant PTEN protein contains 403 amino acids that distribute in two major domains: a catalytic PTP domain and a membranebinding C2 domain (10) . The recently identifi ed and less abundant longer PTEN protein (named as PTEN-Long or PTENα, and here as PTEN-L) contains 173 additional aminoterminal intrinsically disordered amino acids, as a result of the usage of an alternative CUG translation initiation site upstream to the canonical AUG sequence used to produce the shorter 403-amino-acid form (11) (12) (13) .
Different groups have proposed that PTEN-L can be secreted to enter other cells (11) and that it may form heterodimers with PTEN and regulate mitochondrial function (12) . Adding to the functional complexity, PTEN also homodimerizes, which may be particularly important in tumors or patients coexpressing wild-type and mutated PTEN alleles (14) . Mutations encoding residues in the specifi c region of PTEN-L occur in tumors or are reported as polymorphisms (15) (16) (17) (18) (19) , and this region may control PTEN subcellular localization and tumor suppressor activity. For example, this region includes the internalization signal for uptake of PTEN-L into acceptor cells, a postulated physiologic mechanism for tumor suppression, which potentially could be used as a novel therapeutic approach to reconstitute PTEN activity in PTEN-defi cient tumors (11, 20) .
Abundant literature exists using the amino acid numbering from the short PTEN form, but this numbering does not fi t with the amino acid numbering of PTEN-L. In addition, the numbering of the specifi c residues from PTEN-L (1 to 173) is already used to number different residues in PTEN, which could generate confusion. For instance, residues 1 to 22 from PTEN-L form part of a predicted secretion signal peptide, whereas residues 6 to 32 from PTEN contain an overlapping PI(4,5)P 2 -binding motif, nuclear localization signal, and cytoplasmic localization signal (Fig. 1A ) (21) (22) (23) . Thus, we propose a unifi ed numbering to designate amino acids in PTEN and PTEN-L, so as to avoid ambiguity in the identifi cation of PTEN residues from mutated samples or in the precise naming of PTEN residues in experimental work (Fig. 1, B and C). Our proposal is as follows:
• PTEN-Long is named PTEN-L.
• The amino acid numbering of PTEN does not change.
• The amino acid numbering of PTEN-L is followed by -L, for example, Leu • The equivalence between residues from PTEN and PTEN-L is calculated 
• Amino acid changes, either through site-directed mutagenesis or through naturally occurring mutations, are indicated as the residue and number without any extension for PTEN (for example, C124S), and with the -L extension for PTEN-L (for example, C297S-L) when the name of the protein is not immediately preceding the mutation name. Mutations commonly used in experimental work to abrogate the catalytic activity of PTEN are shown in Fig. 1B. • Nucleotide numbering to desig-nate mutations at the PTEN-L-specifi c residues follows the Human Genome Variation Society (HGVS) recommendations (24) . For instance, nucleotides -3 to -1 would encode Asp 173 -L; -6 to -4 would encode Pro 172 -L; up to -519 to -517, which would encode Leu 1 -L (Fig. 1C) . Note that CUG -519 to -517 nucleotides in the HGVSrecommended numbering for human PTEN gene correspond to CUG 513 to 515 nucleotides in the human PTEN cDNA entry (NM_000314).
• Homodimers and heterodimers of PTEN proteins are designated with the appropriate extension as needed (Fig.  1D ).
• Newly identifi ed PTEN proteins with starting amino acids distinct from Met 1 from PTEN or Leu 1 -L from PTEN-L could be named alphabetically as PTEN-M, PTEN-N, and so on, or by using another appropriate capital letter, and the nomenclature for amino acids and amino acid changes would follow the rules as above for PTEN-L.
• The same rules apply to other mammalian PTEN-L protein orthologs, especially those from animal models usually handled in biomedical research. The possibility of numbering PTEN-L-specifi c residues with negative numbers starting at and going upstream from the canonical AUG initiation codon of PTEN (as recommended by the HGVS for mutations that introduce in proteins new translation initiation sites) is not practical in the case of PTEN-L, because this form is produced from a natural, not mutationcreated, upstream alternative translation initiation codon (CUG) that generates a natural longer protein. The mutations affecting the PTEN-L-specifi c residues do not introduce new translation initiation sites, but rather change residues in PTEN-L.
We think that this unifi ed nomenclature will facilitate to both researchers and clinicians the unambiguous identifi cation of amino acids from PTEN and PTEN-L and aid in the description of any new forms that may be identifi ed in the future. 
